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ABSTRACT
PURPOSE To address doubts regarding National Lung Screening Trial (NLST)
generalizability, we analyzed over 6,000 lung cancer screenings (LCSs) within a
community health system.
METHODS Our LCS program included 10 sites, 7 hospitals (2 non-university tertiary

care, 5 community) and 3 free-standing imaging centers. Primary care clinicians
referred patients. Standard criteria determined eligibility. Dedicated radiologists
interpreted all LCSs, assigning Lung Imaging Reporting and Data System (LungRADS) categories. All category 4 Lung-RADS scans underwent multidisciplinary
review and management recommendations. Data was prospectively collected
from November 2013 through December 2018 and retrospectively analyzed.
RESULTS Of 4,666 referrals, 1,264 individuals were excluded or declined, and

3,402 individuals underwent initial LCS. Second through eighth LCSs were performed on 2,758 patients, for a total of 6,161 LCSs. Intervention rate after LCS
was 14.6% (500 individuals) and was most often additional imaging. Invasive
interventions (n = 226) were performed, including 141 diagnostic procedures and
85 surgeries in 176 individuals (procedure rate 6.6%). Ninety-five lung cancers
were diagnosed: 84 non-small cell (stage 1: 60; stage 2: 7; stage 3: 9; stage 4:
8), and 11 small cell lung cancers. The procedural adverse event rate was 23/226
(10.1%) in 21 patients (0.6% of all screened individuals). Pneumothorax (n = 10)
was the most frequent, 6 requiring pleural drainage. There were 2 deaths among
85 surgeries or 2.3% surgical mortality.
CONCLUSIONS Our LCS experience in a community setting demonstrated lung

cancer diagnosis, stage shift, intervention frequency, and adverse event rate
similar to the NLST. This study confirms that LCS can be performed successfully,
safely, and with equivalence to the NLST in a community health care setting.
Ann Fam Med 2020;18:243-249. https://doi.org/10.1370/afm.2519.
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ince 2011, when the National Lung Screening Trial (NLST) results
showed a 20% decrease in lung cancer–specific mortality in a high
risk population,1 lung cancer screening (LCS), using low-dose computed tomography, has been recommended as the standard of care by
most professional and patient advocacy organizations.2-5 Guidelines for
LCS programs have been published6,7 and LCS implementation has been
described.8 The NLST listed as one of the study weaknesses the recognized expertise of the participating medical centers “in radiology and in
the diagnosis and treatment of cancer” which raised the question of the
generalizability of their results to community facilities.1 This concern was
amplified by the American Academy of Family Physicians and contributed
to the organization not endorsing LCS.9,10 To evaluate these concerns, we
aim to describe our LCS program experience within a large metropolitan
non-university, non-NLST, community, tertiary care system.

METHODS
Providence St Joseph Health (PSJH) system is one of the largest integrated systems in the United States and includes multiple outpatient care
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facilities, an insurance product, and 50 hospitals in
Alaska, California, Montana, New Mexico, Oregon,
Texas, and Washington. Integrated systems have internal operational accountability, allowing for comprehensive review of clinical care. Our LCS program operated
in the Portland, Oregon region of the PSJH system.
The program was implemented by the cancer services
group rather than the diagnostic imaging group due to
clinical leadership, program novelty, and lack of a template. The LSC program began operations in November 2013 incorporating 7 hospitals (2 non-university
tertiary and 5 community medical centers) and 3 freestanding imaging centers, in coordination with our
interdisciplinary thoracic oncology program.
Patients were referred by primary care clinicians
within and outside of PSJH. The program process is
illustrated in Figure 1. Initially, shared decision making
was provided by the LCS team, but in 2015, this transitioned to the primary care clinicians at their request
due to their established patient-clincian relationship
leveraging more intimate knowledge of patient-specific
values in shared decision making. Lung cancer screening was carried out using NLST eligibility criteria,
and after February 2015, the Centers for Medicare &
Medicaid Services eligibility criteria (age 55-77 years,
at least 30 packs per year smoking, smoking cessation
less than 15 years, no cancer symptoms, no concomitant life threatening illness, medically fit and willing
to undergo additional indicated medical management
and future LCS).11 Patients not meeting eligibility were
not screened. The required program components6,7
of smoking cessation and patient education were provided by the program coordinator, and after 2015, by
primary care clinicians. Additional patient and clinician
education was provided by a website12 that incorporated risk calculators and shared decision making tools.
Primary care clinicians employed by PSJH ordered
LCS via the electronic health record after eligibility
determination and shared decision making. Non-PSJH
clinicians faxed standardized order forms. A second
eligibility check was carried out by a coordinator or
by a diagnostic radiology team member before the
scan. Lung cancer screening was carried out annually.2
Automated notification of follow-up LCS and patient
reminder letters were initiated in 2017.
All LCS examination techniques were standardized and performed in accordance with the American
College of Radiology standard protocol specifying
acceptable characteristics of the imaging machine and
acquisition variables.6,7 Designated radiologists at the
tertiary centers interpreted all the LCS results using
algorithms for lung nodule identification and imaged
lung nodule management. Interpretation utilized
structured reporting, interpreting via an internally
ANNALS O F FAMILY MEDICINE

✦

designed system (normal, suspicious-probably benign,
suspicious-probably malignant, incidental findingurgent/non-urgent). In 2014, this system was replaced
by the Lung Imaging Reporting and Data System
(Lung-RADS) categories. Briefly, Lung-RADS 1, 2, and
3 are negative (no nodules), benign, and probably benign,
respectively. Category 4 is suspicious, requires further
evaluation, and carries a ≥15% probability of malignancy.13 Every Lung-RADS 4 LCS result underwent
Figure 1. Lung cancer screening process.
LCS process

PCC cancer risk discussion

PCC & patient: shared decision

Shared decision making:
1. Smoking cessation intervention
2. Review benefits & risks of screening
3. Personalize decision with SDM tool

PCC orders CT screening

Low-dose
CT screening

Diagnostic imaging schedules
screening CT with patient

Screening chest CT (0.8-1.5 mSv)

Thoracic radiologist reviews scans and
reports findings to PCC and patient

All lung-RADs 4 scans reviewed
at Providence Multidisciplinary
Thoracic Disease Conference

Treatment and
follow-up

If lung cancer suspected, patient
scheduled with thoracic specialists

Program works with PCC to schedule
follow-up scans if needed

PCC maintains primary patient care role
CT = computed tomography; LCS = lung cancer screening; lung-RADS = Lung
Imaging Reporting and Data System; PCC = primary care clinician;
SDM = shared decision making.
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review by a multidisciplinary thoracic disease conference (MTDC) consisting of physicians from pulmonology, thoracic surgery, medical oncology, radiation
oncology, thoracic pathology, and thoracic radiology
services. The MTDC generated guideline-compliant
management recommendations to the referring primary care clinician, but where ambiguous, with an
intentional program bias towards minimizing interventions. The primary care clinician managed all subsequent activity until referral to specialists.
Physicians involved in the program were from several medical settings, including some PSJH-employed
groups (medical oncology, pathology, and thoracic
surgery) and some fee-for-service groups (radiology,
pulmonology, radiation oncology, and thoracic surgery). A PSJH full-time employee program coordinator recorded all imaging, procedures, adverse events,
pathology, staging, and ensured follow-up LCS. The
coordinator utilized a clinical research database that
included registration (demographics, smoking history),
schedule (all screening computed tomography scans,
next due date), and post visit (scan information, LCSgenerated procedures, or cancer diagnosis). Monthly,
the coordinator generated a list of patients due for
LCS. Each patient was sent 3 reminder letters. The
referring clinician was notified that the patient was
due for follow-up scan. The coordinator tracked the
patients undergoing (or declining) LCS.
In 2014, our program was designated a Screening
Center of Excellence by the Lung Cancer Alliance
patient advocacy group.14
We retrospectively analyzed prospectively collected clinical data on individuals referred to our LCS
program. Data was collected over 62 months (November 2013-December 2018) and analyzed. This study
was approved by the Institutional Review Board (IRB
2018000035).

RESULTS

Demographic

No. (%)

Age, y
55-64

1,114 (44)

65-81

1,399 (56)

Sex
Female

1,265 (50)

Male

1,248 (50)

Race
White

2,159 (86)

Asian

55 (2)

African American

33 (1)

Other

72 (3)

American Indian or Alaska native

15 (<1)

Patient refused

64 (3)

Unknown

115 (4)

Smoking
Former

999 (40)

Current

1,514 (60)

the program or had declined further participation,
and they are not represented in Table 1. The details
of LCSs after the initial screening is shown in Table
2. Figure 2 displays our LCS volume over the study
period. Lung cancer screening Lung-RADs 4 presentations to the MTDC were not tracked until late 2015
and numbered: 48 in 2015, 94 in 2016, 92 in 2017, and
122 in 2018 for a total of 356.
Of the entire screened population, 500 patients
(14.6%) had a result that triggered further investigation
at some point during screening. Of those, 324 underwent additional imaging only. Table 3 depicts imaging
activity in all patients requiring additional investigation (imaging and/or invasive procedures), with 31%
performed outside of PSJH. There were 226 invasive

Table 2. Subsequent Patient Screening After Initial LCS
(N = 3,402)

Of 4,666 referrals, 1,264 individuals were
excluded or declined, and 3,402 individuals
underwent initial LCS. Approximately 30%
of LCS referrals originated from outside
PSJH. Three of 3,402 LCS individuals were
lost to follow-up (0.08%). Second through
eighth LCSs were performed on 2,758
patients, for a total of 6,161 LCSs. Table 1
displays demographic information on the
2,513 people enrolled in the program at
time of data review. The baseline scan total
of 3,402 individuals was an accumulation of
LCSs since 2013. At the time of data capture some of these patients had completed
ANNALS O F FAMILY MEDICINE

Table 1. Demographics of Enrolled Lung Cancer
Screening Patients (N = 2,513)

Activity Type

No. (%)

Enrolled or completed LCS program during study period

2,791 (82)

Did not schedule or declined PCC-ordered LSC

258 (8)

Had diagnostic CTs (from LCS & not from LCS)

79 (2)

Subsequent LCS scans outside PSJH

61 (2)

Initial LCS resulted in diagnosis of cancer, no other LCS

51 (2)

Had repeat scans within PSJH but after end of study period

50 (1)

Changed insurance, other insurance issue, changed PCC, or
had no PCC
PCC declined or did not send subsequent orders

46 (1)

Moved

23 (1)

43 (1)

CT = computed tomography; LCS = lung cancer screening; PCC = primary care clinician;
PSJH = Providence St Joseph Health.
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Table 5. Cancers Diagnosed After Lung Cancer
Screening of 3,402 Individuals (N = 111)

Table 3. Additional Imaging in 500 Patients
Requiring Further Investigation (N = 1,179)
Imaging Type

No.

Chest CT

501

X-ray

317

PET

129

Ultrasound

115

Other CT

55

MRI

35

Vascular imaging

14

Bone scan

4

Echocardiography

3

Bone density

2

Esophagram

2

Mammography

2

Lung Cancer

No.
(n = 95)

NSCLC stage I

60

Renal

4

NSCLC stage II

7

Breast

2

NSCLC stage III

9

Thyroid

1

NSCLC stage IV

8

Colon

1

Limited SCLC

4

Bile duct

1

Extensive SCLC

7

Prostate

1

Multiple myeloma

1

Lymphoma

1

Mesothelioma

1

Thymoma

1

Tonsil

1

Cervical cancer
metastasis

1

CT = computed tomography; MRI = magnetic resonance imaging; PET = positron emitted tomography.

Other Cancer

No.
(n = 16)

NSCLC = non-small–cell lung cancer; SCLC = small cell lung cancer.

Table 4. Invasive Interventions in 176 Patientsa
(N = 226)
Procedure Type

No.

Invasive diagnostic procedures

141

Bronchoscopy

62

CT-guided biopsy
(lung/liver/spine/lymph node/abdomen)
US-guided thyroid biopsy

31
(27/1/1/1/1)
23

US-guided non-thyroid biopsy

8

Endoscopic ultrasound

4

Esophagogastroduodenoscopy

4

Thoracentesis

3

Coronary angiography

3

Flexible laryngoscopy

2

Bone marrow biopsy

1

Surgeries

85

Thoracoscopic lobectomy

37

Thoracoscopic anatomic segmentectomy

11

Thoracoscopic wedge resection

7

Endovascular abdominal aneurysm repair

6

Kidney resection

5

Mediastinoscopy

3

Thoracoscopic/robotic thymectomy

3

Laparoscopic adrenalectomy

3

Hernia repair

2

Thyroid resection

2

Thoracoscopic pneumonectomy

1

Repair ascending aortic aneurysm with
AVR/CAB
Aortic valve replacement

1

Thoracoscopic pleural biopsy

1

Mediastinal mass resection

1

Hepatectomy/Cholecystectomy

1

1

AVR = aortic valve replacement; CAB = coronary artery bypass; CT = computed
tomography; US = ultrasound.
Total number of procedures greater than 176 as some patients underwent
multiple procedures.

a
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procedures were performed in 176 patients, with
or without imaging (Table 4), with 17% performed
outside PSJH. Invasive diagnostic procedures were
performed in 121 patients, the majority being bronchoscopy. Surgery was performed in 81 patients, the
majority for a diagnosed malignancy (thoracic or extrathoracic). Among 56 pulmonary resections for anticipated malignancy, 7 (12%) ultimately proved to be
benign. None of the 7 patients experienced an adverse
event. All lung resections were thoracoscopic.
A total of 111 malignancies were diagnosed in
3,402 screened individuals. There were 95 lung cancers detected and 16 other malignancies (Table 5). Of
note, early stage non-small cell cancer was detected in
67 patients (70% of diagnosed lung cancer) where surgical resection is the preferred treatment. Among early
clinical stage lung cancer patients, 25 did not undergo
resection: 1 refused any further evaluation, 18 were
poor surgical candidates and underwent ablative radiation, 6 refused surgery, opting for ablative radiation.
Of lung cancers diagnosed, 49% were detected on the
initial LCS and the remaining 51% were detected during follow-up LCS.
Table 6 shows 23 procedure-related adverse events
in 21 patients (0.6% of screened population), including 2
deaths (1 after thoracopic lobectomy and 1 after repair
of ascending aortic aneurysm with concomitant aortic
valve replacement and coronary artery bypass). The
most common diagnostic complication was pneumothorax as the majority of procedures were either bronchoscopy or percutaneous lung biopsy. Of 10 patients
with pneumothorax, 6 required a chest tube. Total
procedure-related complication rate was 23/226 (10.1%).
Surgery overall complication rate was 11/85 (12.9%) and
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30 day or surgery hospitalization mortality 2/84 (2.3%).
Examining only thoracic surgery, the complication rate
was 8/64 (12.5%) with 1/64 (1.5%) thoracic surgery 30
day or surgery hospitalization mortality.

DISCUSSION
Given the endorsement of LCS by most patient advocacy and professional organizations,2-5 health care
delivery systems have been striving to implement LCS
programs.8,15 Lung cancer screening provides for a stage
shift to potentially curable lung cancer.1 Indeed, stage
shift is the fundamental tenet of cancer screening. The
utility of cancer screening in a well but at-risk population, however, is predicated upon disease-specific survival improvement in the setting of minimal harm.16
The concern expressed regarding the generalizability of the outcomes reported by the National
Lung Screening Trial1 was amplified by the American
Academy of Family Physicians (AAFP), representing
175,300 physicians and medical students nationwide.17
The AAFP stated, “The NLST… favorable results were
conducted in major medical centers with strict follow-up
protocols for nodules, have not been replicated in a
community setting… The harms of these follow-up
interventions in a setting with a less strict follow-up
protocol in the community is not known… Much of the
success of this trial is based on the low mortality associated with surgical resection of tumors, which may not
be reproducible in all settings.”9,10 As such, the AAFP
issued: “Grade I recommendation: The AAFP concludes
that the evidence is insufficient to recommend for or
against screening for lung cancer with low-dose comTable 6. Procedure-Related Adverse Events
in 21 Patients (N = 23)
Adverse Events

No.

Diagnostic procedure complications

a

Pneumothorax

12
10

Unplanned ED admission post EBUS for
hypoxemia
Post bronchoscopy pneumonia
Surgery complicationsb

1
1
11

Death

2

Reoperation for bleeding

2

Prolonged air leak

2

Postoperative respiratory failure

2

Chest wall hernia

1

Atrial fibrillation requiring intervention

1

Lung segment torsion requiring completion
lobectomy

1

EBUS = endobronchial ultrasound; ED = emergency department.
a
b

11 patients.
10 patients.
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puted tomography in persons at high risk for lung cancer based on age and smoking history.”9 Further, Huo et
al18 used claims-based administrative data to create study
cohorts with characteristics reflecting LCS eligibility
and lung abnormalities on CT requiring interventions
reported in the NLST (biopsy/cytology, bronchoscopy,
thoracic surgery, other). They created a matchedcontrol cohort to model costs of care and reported
overall complications in greater than 20% of interventions, or double that reported by the NLST, specifically
biopsy 18%, bronchoscopy 36%, and thoracic surgery
51%. Thirteen percent of complications were major.
Modeled complication costs were high. They posited
their results to be representative of community practice
outcomes, advised use of this information in LCS shared
decision making, and cautioned that community-based
LCS would not be equivalent to the NLST. Finally,
Pham et al reported very low LCS utilization (1.9%) in
those eligible,19 perhaps due to the above and/or to the
logistics of implementing a LCS program.
To inform the broad medical trend of LCS implementation and specifically address the NLST generalizability concerns outlined above, we evaluated LCS
results in 3,402 people undergoing a total of 6,161
LCSs within a community, non-NLST, non-university,
metropolitan, large tertiary care system. Compared
with NLST, our population was less white (86% vs
91%), more female (50% vs 41%), older (age >65 years:
56% vs 27%), and had more current smokers (60% vs
48%). Our true positive or lung cancer diagnosis (95
of 3,402 individuals), stage shift (79% non-small cell
lung cancer diagnosed stage 1 or 2), intervention rate
(14.6%), further evaluation after positive LCS dominated by additional imaging vs procedures (CT was the
most common additional imaging modality), procedure
rate (6.6%), procedural adverse events (10.1%), surgical
complications (12.9%), and 30-day or surgery-admission
mortality (2.3%) are very similar to the NLST and the
Veterans Health Administration reports.1,8
Care provided outside of study was not commented
upon in the NLST. Although only 2% of our LCSs were
performed outside PSJH, a substantial minority of our
patients received indicated subsequent care outside
of PSJH (additional imaging 31%, procedures 17%).
This reality of community care is not reflected in our
results, as our LCS coordinator tracked all clinical activity, providing 99.9% follow-up of the 3,402 screened
individuals.
A possible weakness of our study nevertheless pertains to generalizability. Despite Portland PSJH being a
community, non-university health system, our thoracic
oncology program is staffed by chest specialists with
local, regional, or national recognition. This expertise
is reflected in our overall results, which we attribute to
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Figure 2. Cumulative number of lung cancer screens, initial LCS only, and patients diagnosed with
lung cancer.
Total LCS performed

Initial LCS only

Patients with lung cancer

7,000
6,161
6,000

5,000

Counts

4,124
4,000

3,402

3,000
2,687
2,000

2,384

1,453
1,704

1,000

1,027

555
25

0
2013

2014

471

2015

44

67

86

95

2016

2017

2018

2019

Screen date
LCS = lung cancer screening.

long-standing high clinical volume, multidisciplinary
and specialized care,20 and is further manifest by our
use of thoracoscopy for all pulmonary resections, and
our low resection rate for benign disease, none of which
suffered complications. Our LCS construct required
resources, including medical leadership, and importantly, a full-time LCS coordinator. Without these, we
could not have effectively followed and maintained
timely interventions, or provided thorough results
tracking, especially with care rendered outside of PSJH.
Lack of availability of such resources could be a major
limiting factor in the success of an LCS program.
Strengths of our study include the uniform application of our programmatic and clinical practice with
complete catchment of clinical data across a single
large metropolitan health system within a large clinical experience. We report 99.9% complete clinical
follow-up. Additionally, our program complied with
subsequently published program construct guidelines.6,7 Another strength was our high LCS adherence
rate of 82% (Table 2), which was, however, somewhat
lower than the 93-95% rate of the NLST. Finally, a
hidden strength of this study is the rapid adoption
and eager participation in LCS by the primary care
clinician community in the Portland metropolitan area
(Oregon). The primary care clinicians recognized in
ANNALS O F FAMILY MEDICINE
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the NLST high-level clinical information and rapidly
translated it into practice, prior even to their regional
leadership‘s endorsement. The high rate of primary
care clinician acceptance of our LCS program accounts
for the high volume and upward trajectory (Figure 2)
of patients evaluated. In fact, we did not market our
LCS program due to the capacity limitation of having
only a single program coordinator.

CONCLUSIONS
Low-dose computed tomography lung cancer screening
can be done with low intervention and complication
rates in a community non-university setting using, or
more accurately stated, requiring a systematic multidisciplinary approach. This large cohort of screened
patients demonstrates lung cancer diagnosis, stage shift,
intervention frequency, and adverse event rate similar to
the NLST. Our experience demonstrates that LCS can
be done successfully and safely in a community setting.
To read or post commentaries in response to this article, see it
online at http://www.AnnFamMed.org/content/18/3/243.
Key words: early cancer detection; lung cancer screening
Submitted October 11, 2019; accepted November 11, 2019.
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